Bringing Data Analytics to the Design of Optimized Diagnostic Networks in Low- and Middle-Income Countries: Process, Terms and Definitions.
data analytics
diagnostic network optimization
low- and middle-income countries
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
24 Dec 2020
24 Dec 2020
Historique:
received:
30
11
2020
revised:
19
12
2020
accepted:
21
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
31
12
2020
Statut:
epublish
Résumé
Diagnostics services are an essential component of healthcare systems, advancing universal health coverage and ensuring global health security, but are often unavailable or under-resourced in low- and middle-income (LMIC) countries. Typically, diagnostics are delivered at various tiers of the laboratory network based on population needs, and resource and infrastructure constraints. A diagnostic network additionally incorporates screening and includes point-of-care testing that may occur outside of a laboratory in the community and clinic settings; it also emphasizes the importance of supportive network elements, including specimen referral systems, as being critical for the functioning of the diagnostic network. To date, design and planning of diagnostic networks in LMICs has largely been driven by infectious diseases such as TB and HIV, relying on manual methods and expert consensus, with a limited application of data analytics. Recently, there have been efforts to improve diagnostic network planning, including diagnostic network optimization (DNO). The DNO process involves the collection, mapping, and spatial analysis of baseline data; selection and development of scenarios to model and optimize; and lastly, implementing changes and measuring impact. This review outlines the goals of DNO and steps in the process, and provides clarity on commonly used terms.
Identifiants
pubmed: 33374315
pii: diagnostics11010022
doi: 10.3390/diagnostics11010022
pmc: PMC7823670
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Bill and Melinda Gates Foundation
ID : OPP1203377
Références
PLoS One. 2020 Jun 3;15(6):e0233620
pubmed: 32492022
J Int AIDS Soc. 2018 Dec;21(12):e25206
pubmed: 30515997
EClinicalMedicine. 2020 Nov 04;28:100607
pubmed: 33294817
PLoS One. 2013 Nov 13;8(11):e78609
pubmed: 24236026
J Acquir Immune Defic Syndr. 2020 Jul 1;84 Suppl 1:S56-S62
pubmed: 32520916
Clin Infect Dis. 2020 Mar 3;70(6):1014-1020
pubmed: 31321438
Afr J Lab Med. 2020 Sep 21;9(2):1103
pubmed: 33102173
PLoS One. 2019 Aug 26;14(8):e0221586
pubmed: 31449559
PLoS One. 2014 Dec 09;9(12):e114727
pubmed: 25490718
Afr J Lab Med. 2016 Oct 31;5(3):471
pubmed: 28879137
Lancet. 2018 May 12;391(10133):1873-1875
pubmed: 29550031
Clin Infect Dis. 2006 Feb 1;42(3):377-82
pubmed: 16392084
Afr J Lab Med. 2017 Mar 29;6(2):608
pubmed: 28879166
Clin Biochem Rev. 2007 Nov;28(4):179-94
pubmed: 18392122
Bull World Health Organ. 2013 Aug 1;91(8):546-546A
pubmed: 23940398
J Int AIDS Soc. 2019 Sep;22(9):e25337
pubmed: 31515967